Pilot proof-of concept of Tb-161 labelled antibody conjugate in vivo

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26722445%3A_____%2F24%3AN0000251" target="_blank" >RIV/26722445:_____/24:N0000251 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Pilot proof-of concept of Tb-161 labelled antibody conjugate in vivo
Original language description
The result of labelled antibody 161Tb-DOTA-bevacizumab was achieved between January 2024 – April 2024. Monoclonal antibody bevacizumab was separated from the infusion solution of the commercial drug and subsequently conjugated with the DOTA-NHS chelator in presence of 0,2M carbonate buffer. Optimisation of synthesis was done. MALDI TOF was acquired to evaluate a ratio of DOTA to bevacizumab during the different reaction conditions. Optimal ratio was 5-6 DOTA molecules attached to lysine moieties of bevacizumab. After purification from unreacted DOTA-NHS by chromatography on a PD10 column/alternatively by centrifugation, was conjugate labelled with 100 MBq of 161TbCl3 in 0,1M PBS buffer solution.
Czech name
—
Czech description
—

Project
<a href="/en/project/TO01000074" target="_blank" >TO01000074: Efficient Low-energy Electron Cancer Therapy with Terbium-161</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Internal product ID
CVŘ-5738
Numerical identification
—
Technical parameters
The reaction mixture was then stirred at 37℃ for 1 h. Subsequently, radiochemical yield was performed using iTLC-SG. A 0.05 M citrate buffer (pH=5.5) was used as the mobile phase. The labelling yield was determined to be 15%. The labelled conjugate was from unreacted 161Tb purified by HPLC on a TSK gel column used as the stationary phase in 0.06M phosphate buffer (pH=6.98) as the mobile phase. Collected fractions were concentrated on vivsapin500. Preparations with an activity of 5.5 MBq, 8.8 MBq and 3.6 MBq were prepared in this way. All prepared samples were sent to the laboratory of the Institute of Molecular and Translational Medicine, where they were studied on the SKOV-3 mouse model.
Economical parameters
Výsledek je předpokládaným výstupem projektu.
Application category by cost
—
Owner IČO
26722445
Owner name
CVŘ, IFE, ČVUT
Owner country
CZ - CZECH REPUBLIC
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence
Licence fee requirement
Z - Poskytovatel licence na výsledek nepožaduje v některých případech licenční poplatek
Web page
—

Similar results(10)